Rheumatology
Latest news
99 articles · 20 / page
Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis: A Case Series
Three cases of pentosan polysulfate maculopathy occurred after subcutaneous administration for arthritis at much lower cumulative doses than oral use, highlighting retinal toxicity risk and need for early detection.
AI-Detected Coronary Calcium Significantly Predicts Cardiovascular Risk in Patients with Immune-Mediated Inflammatory Diseases
AI-driven analysis of routine chest CTs reveals that coronary artery calcium is highly prevalent and strongly predictive of MACE and mortality in patients with IMIDs, identifying a critical treatment gap in this high-risk population.
Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w
Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression
The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with n
Tofacitinib Reverses Muscle Loss in Rheumatoid Arthritis: Insights from the RAMUS Trial
The RAMUS study demonstrates that the JAK inhibitor tofacitinib significantly increases lower limb muscle volume in patients with rheumatoid arthritis, offering a potential explanation for associated creatinine elevations and a new therapeu
Tofacitinib and Muscle Volume: A Potential Paradigm Shift in Managing Rheumatoid Cachexia
The RAMUS study demonstrates that tofacitinib significantly increases lower limb muscle volume in rheumatoid arthritis patients, potentially explaining associated creatinine elevations and offering a new therapeutic avenue for combating mus
Digital Psychological Intervention Reduces Distress and Improves Quality of Life in Inflammatory Rheumatic Diseases: Results from a Pilot RCT
A 102-participant pilot RCT in Germany found that a self-guided digital psychological intervention produced clinically meaningful reductions in psychological distress and modest improvements in quality of life at 3 months in people with inf
Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
History of Thrombosis and Hematologic Disease Double the Risk of New Clots in Persistently aPL‑Positive Patients: Prospective APS ACTION Registry Analysis
In 1,067 persistently antiphospholipid antibody–positive patients followed for 4,727 person‑years, prior thrombosis and coexistent hematologic disease each conferred ~2‑fold increased risk for new thrombosis; microvascular disease and obesi
Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher pre
EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy: What Clinicians and Researchers Need to Know
EULAR’s first-ever, evidence-based classification criteria for haemochromatosis arthropathy (HA) provide an 8-item, 11-point score (≥5 yields 93.3% specificity, 71.4% sensitivity) to standardize research cohorts of C282Y homozygous patients
EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know
EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care
Long-Term Impact of Treat-to-Target Urate-Lowering Therapy on Ultrasound-Detected Crystal Depositions and Clinical Outcomes: Insights from the 5-Year NOR-Gout Study
The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate co
Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study
In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with pri
UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study
The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA a
Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up
Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to hig
Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective
The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-eff
Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy
The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were simi
Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions
A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi
Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern
A multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is ne
Browse by specialty
Open language-specific specialty feeds and department pages.